细胞周期蛋白D3表达在恶性肿瘤患者中的预后意义：一项荟萃分析。
Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis.
作者信息
Wang Bo, Wang Zijian, Han Lizhi, Gong Song, Wang Yanxue, He Zhiwen, Feng Yong, Yang Zhaohui
机构信息
1Department of Rehabilitation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022 China.
2Department of Orthopedics, Xiangyang Central Hospital Affiliated Hubei University of Arts and Science, Xiangyang, 441021 China.
出版信息
Cancer Cell Int. 2019 Jun 10;19:158. doi: 10.1186/s12935-019-0865-3. eCollection 2019.
BACKGROUND
As a pivotal regulator, cyclin D3 gives play to a crucial value in conversion from the G1 stage to the S stage of cell cycle, which is implicated in tumor progression, especially proliferation and migration. Recent literatures have reported that cyclin D3 could predict survival time of malignancy patients. But, its prognostic role of cyclin D3 in neoplasms remains controversial.
METHODS
Databases involving EMBASE, PubMed and Web of Science were carefully searched, and literatures investigating the prognostic effect of aberrantly expressing cyclin D3 among human cancers were collected for further analysis. We used both hazards ratios and its corresponding 95% confidence intervals to evaluate the connection among the survival rate of malignancy patients and the expression of cyclin D3.
RESULTS
There were 13 eligible researches involving 16 cohorts and 2395 participants which were included in this study. The outcomes suggested that highly expressing cyclin D3 was significantly correlated with worse clinical prognosis of overall survival (HR 1.88; 95% CI 1.31-2.69) and disease specific survival (HR 2.68; 95% CI 1.35-5.31). But there existed no significant connection between the elevated expression of cyclin D3 with disease free survival (HR 2.65; 95% CI 0.83-8.46), recurrence-free survival (HR 2.86; 95% CI 0.82-9.96) and progression-free survival (HR 5.24; 95% CI 0.46-60.25) of diffident kinds of malignancy patients. Moreover, we discovered that elevated cyclin D3 expression was significantly connected with decreased overall survival in lymphoma (HR 3.72; 95% CI 2.18-6.36) while no significant relevance between highly expressing cyclin D3 and the overall survival in breast cancer was obtained (HR 2.12; 95% CI 0.76-5.91).
CONCLUSIONS
This meta-analysis demonstrated that highly expressing cyclin D3 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment.
背景
细胞周期蛋白D3作为一种关键调节因子，在细胞周期从G1期向S期的转换中发挥着至关重要的作用，这与肿瘤进展，尤其是增殖和迁移有关。最近的文献报道，细胞周期蛋白D3可以预测恶性肿瘤患者的生存时间。但是，细胞周期蛋白D3在肿瘤中的预后作用仍存在争议。
方法
仔细检索了包括EMBASE、PubMed和Web of Science在内的数据库，并收集了研究细胞周期蛋白D3异常表达在人类癌症中的预后作用的文献进行进一步分析。我们使用风险比及其相应的95%置信区间来评估恶性肿瘤患者生存率与细胞周期蛋白D3表达之间的关联。
结果
本研究纳入了13项符合条件的研究，涉及16个队列和2395名参与者。结果表明，细胞周期蛋白D3高表达与总生存期（HR 1.88；95%CI 1.31 - 2.69）和疾病特异性生存期（HR 2.68；95%CI 1.35 - 5.31）较差的临床预后显著相关。但是，细胞周期蛋白D3表达升高与不同类型恶性肿瘤患者的无病生存期（HR 2.65；95%CI 0.83 - 8.46）、无复发生存期（HR 2.86；95%CI 0.82 - 9.96）和无进展生存期（HR 5.24；95%CI 0.46 - 60.25）之间不存在显著关联。此外，我们发现细胞周期蛋白D3表达升高与淋巴瘤患者总生存期降低显著相关（HR 3.72；95%CI 2.18 - 6.36），而细胞周期蛋白D3高表达与乳腺癌患者总生存期之间未发现显著相关性（HR 2.12；95%CI 0.76 - 5.91）。
结论
这项荟萃分析表明，细胞周期蛋白D3高表达可能是各类恶性肿瘤患者不良预后的生物标志物，这可为临床诊断和治疗提供重要参考。
Zotero 插件